Oppenheimer Reiterates Outperform Rating on argenx SE (ARGX)

Oppenheimer analyst Leland Gershell reiterated an Outperform rating and $778.00 price target on argenx SE (NASDAQ: ARGX).

The analyst comments "ARGX announced positive Phase 3 results on IV Vyvgart in seronegative myasthenia gravis (snMG), with the MG-ADL primary endpoint achieving statistical significance (p=0.0068 vs. placebo). This subgroup (15-20% of MG) lacks antibodies to acetylcholine receptors—making them more difficult to treat and delaying diagnosis. As enabled by next-year's anticipated FDA label expansion, ARGX sees an additional 11K US patients addressable, of whom many will have no other approved option. We expect the ADAPT-SERON results, to be presented in detail at an upcoming medical meeting, to also drive snMG regulatory submissions in other geographies. Today's outcome increases our optimism for a positive Phase 3 ocular MG readout in 1H26 (+7K US patients). We continue to see ARGX as a core biotech holding and reiterate Outperform."

For an analyst ratings summary and ratings history on argenx SE click here. For more ratings news on argenx SE click here.

Shares of argenx SE closed at $660.00 yesterday.

You May Also Be Interested In

• U.S. Navy-led JMIC: U.S. military will begin enforcement of a naval blockade of all Iranian ports and Iranian coastal areas at 2000 GMT on 14 July
• Raymond James on SpaceX (SPCX): 'Starship Sees Accelerating Cadence for Test Launch 13'
• Q32 Bio Inc. (QTTB) PT Raised to $36 at Mizuho